ATB ICPI study, Version 1.0
Research type
Research Study
Full title
Qualification of antibiotic-induced gut perturbation as a therapeutically actionable driver of anti-cancer immunity.
IRAS ID
268247
Contact name
David Pinato
Contact email
Sponsor organisation
Imperial College London
Eudract number
n/a
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Cancers behave differently in some patients compared to others; that is tumours will grow at different rates and will respond differently to treatment. When a patient is diagnosed with cancer it is difficult to predict how the cancer will grow.
We know that Immune checkpoint inhibitor (ICPI) therapy improves the survival of patients across malignancies. However, exposure to broad-spectrum antibiotic therapy (ATB) may abrogate anti-tumour efficacy of ICPIs. The purpose of this study is to understand the relationship between using antibiotic therapy (ATB) and the ICPI response to treatment.
This would mean that in the future, alternative approaches to treatment might be more effective to individual patients with these cancers. We will be carrying out analysis on samples but this will not have any implications to the future treatment of patients enrolled.REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
19/EE/0277
Date of REC Opinion
4 Nov 2019
REC opinion
Further Information Favourable Opinion